BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 20713528)

  • 1. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
    Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
    Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.
    Wu L; Zhao JC; Kim J; Jin HJ; Wang CY; Yu J
    Cancer Res; 2013 Oct; 73(19):6068-79. PubMed ID: 23913826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.
    Ratz L; Laible M; Kacprzyk LA; Wittig-Blaich SM; Tolstov Y; Duensing S; Altevogt P; Klauck SM; Sültmann H
    Oncotarget; 2017 Apr; 8(15):25115-25130. PubMed ID: 28445989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
    Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
    Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
    Chakravarthi BVSK; Chandrashekar DS; Hodigere Balasubramanya SA; Robinson AD; Carskadon S; Rao U; Gordetsky J; Manne U; Netto GJ; Sudarshan S; Palanisamy N; Varambally S
    Prostate; 2018 Dec; 78(16):1311-1320. PubMed ID: 30051493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha.
    Jiang YG; Luo Y; He DL; Li X; Zhang LL; Peng T; Li MC; Lin YH
    Int J Urol; 2007 Nov; 14(11):1034-9. PubMed ID: 17956532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.
    Li Y; Kong D; Wang Z; Ahmad A; Bao B; Padhye S; Sarkar FH
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1495-506. PubMed ID: 21680704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
    Mani RS; Iyer MK; Cao Q; Brenner JC; Wang L; Ghosh A; Cao X; Lonigro RJ; Tomlins SA; Varambally S; Chinnaiyan AM
    Cancer Res; 2011 Aug; 71(16):5387-92. PubMed ID: 21676887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.
    Griner NB; Young D; Chaudhary P; Mohamed AA; Huang W; Chen Y; Sreenath T; Dobi A; Petrovics G; Vishwanatha JK; Sesterhenn IA; Srivastava S; Tan SH
    Mol Cancer Res; 2015 Feb; 13(2):368-79. PubMed ID: 25344575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation.
    Jin X; Jeon HY; Joo KM; Kim JK; Jin J; Kim SH; Kang BG; Beck S; Lee SJ; Kim JK; Park AK; Park WY; Choi YJ; Nam DH; Kim H
    Cancer Res; 2011 Apr; 71(8):3066-75. PubMed ID: 21363911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.
    Singareddy R; Semaan L; Conley-Lacomb MK; St John J; Powell K; Iyer M; Smith D; Heilbrun LK; Shi D; Sakr W; Cher ML; Chinni SR
    Mol Cancer Res; 2013 Nov; 11(11):1349-61. PubMed ID: 23918819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
    Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
    Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.
    Magistroni V; Mologni L; Sanselicio S; Reid JF; Redaelli S; Piazza R; Viltadi M; Bovo G; Strada G; Grasso M; Gariboldi M; Gambacorti-Passerini C
    PLoS One; 2011; 6(11):e28162. PubMed ID: 22140532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling.
    Nath D; Li X; Mondragon C; Post D; Chen M; White JR; Hryniewicz-Jankowska A; Caza T; Kuznetsov VA; Hehnly H; Jamaspishvili T; Berman DM; Zhang F; Kung SHY; Fazli L; Gleave ME; Bratslavsky G; Pandolfi PP; Kotula L
    Cell Commun Signal; 2019 Sep; 17(1):120. PubMed ID: 31530281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of soy-based changes in Wnt-frizzled signaling in prostate cancer.
    Liss MA; Schlicht M; Kahler A; Fitzgerald R; Thomassi T; Degueme A; Hessner M; Datta MW
    Cancer Genomics Proteomics; 2010; 7(5):245-52. PubMed ID: 20952759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
    Kao CJ; Martiniez A; Shi XB; Yang J; Evans CP; Dobi A; deVere White RW; Kung HJ
    Oncogene; 2014 May; 33(19):2495-503. PubMed ID: 23728339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.